Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683800 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,186
- Enrollment target
NCT00683800: Completed Phase 3 study, sponsored by Pfizer.
NCT00683800 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 2,186 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (183% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683800, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,186 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
Primary Outcome
The average daily number of moderate and severe hot flushes was calculated as the sum of the number of moderate and severe hot flushes on each day divided by the number of days with data. Moderate hot flushes: sensation of heat with sweating; able to continue activity; and severe hot flushes: sensation of heat with sweating; causing cessation of activity.
Interventions
- DRUG Placebo
- DRUG desvenlafaxine succinate (DVS) SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,186 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00683800 record still lists
NCT00683800 is an interventional study that assigns participants to a tested intervention. Its 2,186 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (183% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00683800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00683800 about?
NCT00683800 is a clinical study titled "Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women". The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
What is the current status of trial NCT00683800?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,186 participants. The study started on 2008-06. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00683800?
The interventions under investigation include: Placebo (DRUG), desvenlafaxine succinate (DVS) SR (DRUG).
Who is sponsoring clinical trial NCT00683800?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00683800's enrollment target sits among peer trials
2,186 95th of 2000 higher than 1,906 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05917652 · 2,183 participants
The Actuate-CBC Study
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia